Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease.
- L. Bloudek, D. E. Spackman, M. Blankenburg, S. Sullivan
- Psychology, Medicine
- Journal of Alzheimer's disease : JAD
- 2011
Mild Alzheimer's disease (AD) is often difficult to differentiate from mild cognitive impairment (MCI) or non-AD dementias. A multitude of diagnostic biomarkers and advanced imaging strategies have… Expand
Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)
- L. Bloudek, M. Stokes, +10 authors P. Martelletti
- Medicine
- The Journal of Headache and Pain
- 29 May 2012
Migraine is a disabling neurological disease that affects 14.7 % of Europeans. Studies evaluating the economic impact of migraine are complex to conduct adequately and with time become outdated as… Expand
The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients
- R. Rendas-Baum, L. Bloudek, G. Maglinte, S. Varon
- Medicine
- Quality of Life Research
- 15 July 2012
ObjectiveThe Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) has been shown to have good psychometric performance in measuring headache impact in migraine patients, but its… Expand
The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK
- A. J. Batty, R. Hansen, +5 authors S. Sullivan
- Medicine
- Journal of medical economics
- 7 May 2013
Abstract Background: Although chronic migraine is associated with substantial disability and costs, few treatments have been shown to be effective. OnabotulinumtoxinA (Botox, Allergan Inc., Irvine,… Expand
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.
- A. Roy, J. Kish, +5 authors K. Migliaccio-Walle
- Medicine
- American health & drug benefits
- 22 June 2015
BACKGROUND
Multiple myeloma is a progressive cancer for which there is no cure. Despite treatment, almost all patients eventually experience periods of disease relapse and remission. With the… Expand
Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine
- R. Rendas-Baum, M. Yang, S. Varon, L. Bloudek, R. Degryse, M. Kosinski
- Medicine
- Health and Quality of Life Outcomes
- 1 August 2014
BackgroundThe Headache Impact Test (HIT)-6 was developed and has been validated in patients with various types of headache. The objective of this study was to report the psychometric properties of… Expand
Systematic review of migraine prophylaxis adherence and persistence.
- Z. Hepp, L. Bloudek, S. Varon
- Medicine
- Journal of managed care pharmacy : JMCP
- 2014
BACKGROUND
Migraine is a common neurological disease affecting 12% of Americans and millions worldwide. Medication adherence has been studied extensively in many chronic conditions, with poor… Expand
Adherence with Migraine Prophylaxis in Clinical Practice
- A. Berger, L. Bloudek, S. Varon, G. Oster
- Medicine
- Pain practice : the official journal of World…
- 1 September 2012
Objective: To characterize adherence with antidepressants, antiepileptic drugs, and beta blockers as prophylaxis against migraine in typical clinical practice.
Treatment Persistence and Switching in Triptan Users: A Systematic Literature Review
- A. Messali, M. Yang, +4 authors S. Kori
- Medicine
- Headache
- 1 July 2014
To conduct a systematic review to evaluate persistence to and switching of triptan therapy for the acute treatment of migraine.
Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
- L. Bloudek, A. Roy, +5 authors E. Kuriakose
- Medicine
- Journal of managed care & specialty pharmacy
- 26 July 2016
BACKGROUND
Multiple myeloma is an incurable B-cell malignancy with a natural history that involves alternating periods of remission and subsequent relapse. For relapsed and/or refractory multiple… Expand